Discover undervalued stocks with Eulerpool.

Subscribe for $2

Amgen Stock AMGN

Price

0
Today +/-
-0
Today %
-0 %

Amgen stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Amgen stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Amgen stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Amgen stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Amgen's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Amgen Stock Price History

DateAmgen Price
10/8/20250 undefined
10/8/2025295.96 undefined
10/7/2025295.55 undefined
10/6/2025294.13 undefined
10/3/2025300.64 undefined
10/3/2025298.01 undefined
10/2/2025297.41 undefined
10/1/2025299.11 undefined
9/29/2025282.20 undefined
9/28/2025273.97 undefined
9/25/2025272.98 undefined
9/24/2025271.18 undefined
9/24/2025279.23 undefined
9/23/2025286.01 undefined
9/22/2025286.01 undefined
9/19/2025285.26 undefined
9/19/2025285.42 undefined
9/18/2025274.80 undefined
9/17/2025274.72 undefined
9/16/2025273.21 undefined
9/15/2025274.41 undefined
9/12/2025276.71 undefined
9/11/2025282.74 undefined
9/10/2025278.52 undefined
9/9/2025278.52 undefined
9/8/2025280.21 undefined

Amgen Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Amgen, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Amgen from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Amgen’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Amgen. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Amgen’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Amgen’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Amgen’s growth potential.

Amgen Revenue, EBIT and net profit per share

DateAmgen RevenueAmgen EBITAmgen Net Income
2030e41.09 B undefined0 undefined14 B undefined
2029e39.48 B undefined17.42 B undefined13.13 B undefined
2028e38.27 B undefined16.84 B undefined12.61 B undefined
2027e37.99 B undefined16.38 B undefined12.37 B undefined
2026e37.03 B undefined16.18 B undefined11.92 B undefined
2025e36.41 B undefined16.02 B undefined11.63 B undefined
202433.42 B undefined9.66 B undefined4.09 B undefined
202328.19 B undefined8.16 B undefined6.72 B undefined
202226.32 B undefined10.13 B undefined6.55 B undefined
202125.98 B undefined9.14 B undefined5.89 B undefined
202025.42 B undefined9.14 B undefined7.26 B undefined
201923.36 B undefined9.72 B undefined7.84 B undefined
201823.75 B undefined10.64 B undefined8.39 B undefined
201722.85 B undefined10.34 B undefined1.98 B undefined
201622.99 B undefined9.79 B undefined7.72 B undefined
201521.66 B undefined8.53 B undefined6.94 B undefined
201420.06 B undefined6.57 B undefined5.16 B undefined
201318.68 B undefined6.17 B undefined5.08 B undefined
201217.27 B undefined5.82 B undefined4.35 B undefined
201115.58 B undefined5.2 B undefined3.68 B undefined
201015.05 B undefined6.97 B undefined4.63 B undefined
200914.64 B undefined6.81 B undefined4.61 B undefined
200815 B undefined5.52 B undefined4.05 B undefined
200714.77 B undefined5.25 B undefined3.08 B undefined
200614.27 B undefined5.01 B undefined2.95 B undefined
200512.43 B undefined4.84 B undefined3.67 B undefined

Amgen Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B)
NET INCOME (B)
NET INCOME GROWTH (%)
DIV. ()
DIV. GROWTH (%)
SHARES (B)
DOCUMENTS
19821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
000.010.020.030.040.070.150.30.681.091.371.651.942.242.42.723.343.634.025.528.3610.5512.4314.2714.771514.6415.0515.5817.2718.6820.0621.6622.9922.8523.7523.3625.4225.9826.3228.1933.4236.4137.0337.9938.2739.4841.09
--233.33130.0030.4346.6759.09111.43102.03128.0960.2625.7119.9417.7215.467.1913.2022.888.6510.6637.5251.2926.2617.8214.793.531.57-2.412.813.5110.808.177.437.976.14-0.623.93-1.628.832.181.327.0918.578.941.692.590.753.174.08
-100.00229,660.0099,852.17100.00100.00100.0087.8479.6083.4383.0783.9985.5685.9387.3787.4687.3187.9688.7688.9786.6783.9583.5983.2585.3282.7584.7085.7285.2582.6281.4782.0877.9680.4981.9082.1982.7381.3575.7775.1675.6670.1568.7163.0762.0260.4660.0158.1755.89
00000.030.040.070.130.240.570.911.151.411.671.962.12.372.943.223.574.797.028.8210.3512.1712.2212.7112.5512.8312.8714.0715.3315.6417.4418.8318.7819.6519.0119.2719.5319.9219.7822.97000000
-0.01-0.01-0.01000-0.01000.10.360.380.320.540.680.640.861.11.141.12-1.392.262.363.672.953.084.054.614.633.684.355.085.166.947.721.988.397.847.265.896.556.724.0911.6311.9212.3712.6113.1314
--28.5760.00-112.50-100.00-500.00-150.00-2,350.00265.316.98-16.4568.1326.39-5.2934.0127.003.92-1.67-224.29-262.364.5655.48-19.714.3431.6413.650.48-20.4017.9716.941.5234.5311.28-74.37324.15-6.58-7.37-18.8711.182.52-39.11184.302.523.721.974.116.69
-----------------------------1.231.552.022.623.374.154.775.415.956.567.227.958.649.139.5213.9314.5814.7915.4016.46
00000000000000000000000000000026.0230.3229.728.6323.1514.9413.429.9810.2510.0610.118.685.674.2746.324.671.444.126.88
0.110.430.520.560.720.830.810.821.061.191.181.161.131.141.121.11.061.081.091.081.151.351.321.261.191.121.081.020.970.910.780.770.770.770.750.740.670.610.590.570.540.540.54000000
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Amgen Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Amgen is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (B)
RECEIVABLES (B)
OTHER REC. (M)
INVENTORIES (B)
OTHER CURRENT LIAB. (B)
CURRENT ASSETS (B)
TANGIBLE ASSETS (B)
LONG-T. INVEST. (B)
LONG-T. REC. (M)
INTANGIBLE ASSETS (B)
GOODWILL (B)
OTHER NON-CURRENT ASSETS (B)
NON-CURRENT ASSETS (B)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (B)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (B)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (B)
LIABILITIES (B)
PROVISIONS (B)
OTHER SHORT-TERM LIAB. (B)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (B)
SHORT-TERM REC. (B)
LONG-T. LIAB. (B)
DEFERRED TAXES (B)
OTHER LIAB. (B)
LONG-T. LIABILITIES (B)
DEBT (B)
TOTAL CAPITAL (B)
1982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                                                     
0.010.040.020.070.060.110.070.080.170.380.560.720.71.051.081.031.281.332.032.664.665.125.815.266.287.159.5513.4417.4220.6424.0619.427.0331.3838.0941.6829.38.9110.658.049.3110.9411.97
00000.010.010.020.030.040.090.160.160.20.20.230.270.320.410.390.50.751.011.461.772.122.12.072.112.342.92.522.72.5533.173.243.584.064.534.95.567.276.78
00000000000000000000000000000000000000799944829674719
0000000.020.030.030.040.060.080.10.090.10.110.110.180.310.360.550.710.891.261.92.092.082.222.022.482.743.022.652.442.752.832.943.583.894.094.939.527
00000000.040.040.080.110.090.130.120.10.140.160.140.220.340.440.561.010.951.411.71.521.161.351.571.892.252.491.72.021.731.791.891.281.421.561.932.56
0.010.040.020.070.070.120.10.180.290.590.871.051.121.451.51.541.862.072.943.866.47.49.179.2411.7113.0415.2218.9323.1327.5931.2127.3734.7138.5246.0149.4837.6218.4421.1419.3922.1930.3329.03
0.010.010.010.010.020.060.110.120.150.250.430.590.670.740.911.191.451.551.781.952.813.84.715.045.925.945.885.745.525.425.335.355.224.914.964.994.965.45.35.756.016.597.1
000000000.020.020.060.060.080.10.110.120.120.13000000.180.240.290.360.310.380.403.41000.50.57001.180.570.250.250.26
0000000000000000000000000000000000000000000
00000000000000000000.034.84.294.033.743.753.332.992.572.232.583.9713.2612.6911.6410.288.617.4419.4116.5915.1816.0832.6427.7
00000000000000000000.19.879.8210.5310.511.311.2411.3411.3411.3311.7512.6614.9714.7914.7914.7514.7614.714.714.6914.8915.5318.6318.64
00.010.010.010.010.0200.010.010.010.020.070.130.140.240.260.240.330.680.510.570.80.780.610.870.790.640.750.891.121.131.771.591.61.121.551.71.754.065.395.078.719.11
0.010.020.020.020.030.070.110.130.180.280.50.710.880.981.261.571.812.012.462.5818.0518.7120.0520.0622.0821.621.2120.720.3621.2823.0938.7634.332.9331.6230.4828.841.2741.841.7842.9466.8262.81
0.010.060.050.10.10.190.210.310.460.871.371.771.992.432.773.113.674.085.46.4424.4626.1129.2229.333.7934.6436.4339.6343.4948.8754.366.1369.0171.4577.6379.9566.4259.7162.9561.1765.1297.1591.84
                                                                                     
0.020.060.06000000000000000000000024.9826.4426.9427.327.7829.3429.8930.4130.6530.7830.9931.2531.5331.832.132.5133.0733.53
0000.10.10.180.190.20.320.440.570.640.720.871.031.221.672.072.953.4719.342022.0823.5624.16000000000000000000
-0.01-0.01-0.02-0.02-0.02-0.02-0.03-0.01-0.010.090.360.540.560.810.880.940.890.971.311.69-1.13-0.67-2.38-3.13-5.2-7.16-5.67-4.32-3.51-8.92-10.42-7.63-4.62-2.09-0.44-5.07-17.98-21.33-21.41-24.6-28.62-26.55-27.59
000000000000000-22-4-15635667613221253117-501851-37-11811-220-333-535-431-550-986-796-231-289-66
00000000000000000000000000095135120183-43-19-260-138-144-3382210000
0.010.050.040.080.080.160.160.190.310.530.931.171.271.671.912.142.563.024.325.2218.2919.3919.7120.4518.9617.8720.8922.6723.9419.0319.0622.125.7828.0829.8825.2412.59.679.416.73.666.235.88
000000.010.010.010.010.030.040.020.030.050.080.10.120.080.140.140.260.330.510.60.560.380.50.570.720.640.910.791.210.970.921.351.211.371.421.371.5718.5421.46
00000000.030.070.260.270.280.410.460.450.610.660.650.620.771.152.132.4833.533.613.383.33.375.033.783.654.375.454.965.566.957.578.38.9510.1912.4913.78
00000000.010.010000000000000001.060.1900001.011.010.9200.920.950.910.951.851.782.332.873.86
1000000000011010070001001001001001230000000000000000000000
000000000000000.120.030.01000001.1701.82102.490.082.52.510.52.254.41.154.422.950.090.091.591.443.55
00000.010.010.010.060.090.30.310.410.540.580.640.740.890.830.8611.532.464.163.66.946.184.893.876.575.758.197.957.018.6611.29.0213.4912.8411.6512.1815.6935.3442.65
00.010.010.010.010.020.030.070.060.040.130.180.180.180.060.230.220.220.220.223.053.083.943.967.219.188.3510.610.8721.3424.0329.6230.2229.1830.1934.1929.5126.9532.933.2237.3563.1756.55
000000000000000000001.591.151.291.160.370.48000003.53.462.242.441.170.860.610002.351.62
000000000000000.160000000.040.130.130.30.932.32.492.12.743.012.962.553.283.9210.3410.059.648.999.068.427.014.7
00.010.010.010.010.020.030.070.060.040.130.180.180.180.220.230.220.220.220.224.644.275.365.257.8810.5910.6613.0912.9724.0927.0536.0836.2234.736.5545.6940.4337.241.8942.2845.7772.5362.86
00.010.010.010.010.030.040.120.150.340.440.590.720.760.860.971.111.051.091.236.176.729.528.8514.8216.7715.5416.9619.5429.8435.2444.0343.2343.3747.7554.7153.9250.0353.5454.4761.46107.87105.51
0.010.060.050.090.10.190.210.310.460.871.381.771.992.432.773.113.674.085.46.4424.4626.1129.2229.333.7934.6436.4339.6343.4948.8754.366.1369.0171.4577.6379.9566.4259.7162.9561.1765.12114.1111.39
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Amgen provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Amgen's financial health and stability.

Assets

Amgen's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Amgen must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Amgen after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Amgen's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)
DEPRECIATION (B)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (B)
NON-CASH ITEM (B)
PAID INTEREST (B)
PAID TAXES (B)
NET CASH FLOW FROM OPERATING ACTIVITIES (B)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (B)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (B)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (B)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (B)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
1985198619871988null19891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
000-0.01-0.01000.10.360.380.320.540.680.640.861.11.141.12-1.392.262.363.672.953.084.054.614.633.684.355.085.166.947.721.988.397.847.265.896.556.72
0000.010.010.010.020.020.030.050.080.080.10.120.140.180.210.270.450.690.730.840.961.21.071.051.021.061.091.292.092.112.111.961.952.213.63.43.424.07
000000-19-49-81722426-31000-148175-19057-95-54056-13747-151-32828-189-108-607183-1,330-363-289-287-453-1,198-1,273
0-00-0.02-0.02-0.040.040.16-0.08-0.04-0.020.07-0.040.14-0-0.23-0.12-0.1-0.250.44-0.380.010.46-0.440.430.11-0.320.29-0.05-0.391.121.1207.910.62-0.73-0.22-1.19-0.73-0.48
0000.010.010.01-0.01-0.02-0.010.020.150.050.050.040.150.180.410.343.270.370.920.481.551.510.840.810.960.750.830.910.70.50.650.991.010.430.471.962.08-0.13
000000000.01000.0100.010.020.010.030.030.020.020.010.080.120.260.30.290.320.450.410.931.11.11.31.31.51.31.21.21.22.4
0000000.030.060.130.150.230.10.250.180.250.320.140.520.440.41.140.840.990.90.670.51.340.60.50.320.270.921.11.51.91.91.41.92.43.4
000.01-0.01-0.01-0.010.040.210.290.430.530.770.820.91.151.231.641.482.253.573.74.915.395.45.996.345.795.125.886.298.569.7310.3511.1811.39.1510.59.269.728.47
-5-12-36-43-43-42-55-117-220-210-131-163-267-388-408-304-438-442-659-1,357-1,336-867-1,218-1,267-672-530-580-567-689-693-1,003-594-837-664-738-618-608-880-936-1,112
-0-0.05-0.10.010.01-0.02-0.13-0.23-0.47-0.39-0.19-0.69-0.31-0.3-0.67-0.46-1.04-0.54-2.86-3.21-1.4-0.06-5.13-1.99-3.17-3.2-4.15-0.79-9.99-8.47-5.75-5.55-8.66-4.0214.345.71-5.40.73-6.04-26.2
0-0.04-0.060.050.050.02-0.07-0.11-0.25-0.18-0.06-0.53-0.040.09-0.27-0.16-0.6-0.1-2.21-1.85-0.060.81-3.91-0.73-2.49-2.67-3.57-0.22-9.3-7.78-4.75-4.95-7.82-3.3615.086.33-4.791.61-5.11-25.09
0000000000000000000000000000000000000000
0-00.010.010.010.050.05-0.020.090.16-0.01-0.04-0.070.080.10002.77-0.121.99-1.18-0.212.14-1.010.982.477.894.814.68-1.131.073.590.07-1.12-4.512.460.86.6225.68
422787776488-34-180-241-183-337-604-567-776-466-460-993-1,272-3,619-3,343-698-4,823-2,113-3,208-3,706-8,073-3,319-53648-1,867-2,910-3,160-17,794-7,702-3,486-4,975-6,3600
0.0400.090.020.020.060.130.110.13-0.01-0.26-0.22-0.41-0.53-0.51-0.83-0.5-0.481.78-1.37-1.61-4.54-0.82-2.67-3.07-2.02-1.23-0.670.422.73-2.88-3.77-2.6-6.59-22.49-15.77-4.87-8.27-4.0421.05
00000-114456913-8-4-4-9-47-58-37-1862421-2097134920431246-655-573-284-140-68-42-90-78-103-72
000000000000000000000000000-500-1,118-1,415-1,851-2,396-2,998-3,365-3,507-3,509-3,755-4,013-4,196-4,556
0.04-0.05-00.020.020.020.030.09-0.050.040.08-0.150.10.07-0.04-0.070.10.461.16-1.020.690.31-0.560.74-0.251.110.43.66-3.690.55-0.070.41-0.90.563.15-0.910.231.72-0.363.32
-1-10-30-490-56-2094732234016105565157429231,1971,0381,5902,2102,3614,0444,1714,1345,3165,8065,2074,5525,1935,5987,5529,1379,51710,51310,5588,5329,8898,3818,7857,359
0000000000000000000000000000000000000000

Amgen stock margins

The Amgen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Amgen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Amgen.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Amgen's sales revenue. A higher gross margin percentage indicates that the Amgen retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Amgen's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Amgen's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Amgen's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Amgen. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Amgen's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Amgen Margin History

Amgen Gross marginAmgen Profit marginAmgen EBIT marginAmgen Profit margin
2030e68.71 %0 %34.08 %
2029e68.71 %44.13 %33.25 %
2028e68.71 %43.99 %32.94 %
2027e68.71 %43.11 %32.55 %
2026e68.71 %43.69 %32.2 %
2025e68.71 %43.99 %31.94 %
202468.71 %28.9 %12.24 %
202370.15 %28.96 %23.83 %
202275.66 %38.49 %24.89 %
202175.16 %35.2 %22.68 %
202075.77 %35.95 %28.57 %
201981.35 %41.61 %33.57 %
201882.73 %44.78 %35.35 %
201782.19 %45.25 %8.66 %
201681.9 %42.57 %33.59 %
201580.49 %39.38 %32.03 %
201477.96 %32.74 %25.71 %
201382.08 %33.01 %27.21 %
201281.47 %33.69 %25.17 %
201182.62 %33.38 %23.64 %
201085.25 %46.28 %30.74 %
200985.72 %46.48 %31.45 %
200884.7 %36.81 %27.01 %
200782.75 %35.52 %20.84 %
200685.32 %35.11 %20.68 %
200583.25 %38.93 %29.56 %

Amgen Stock Sales Revenue, EBIT, Earnings per Share

The Amgen earnings per share therefore indicates how much revenue Amgen has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Amgen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Amgen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Amgen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Amgen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Amgen Revenue, EBIT and net profit per share

DateAmgen Sales per ShareAmgen EBIT per shareAmgen Earnings per Share
2030e75.96 undefined0 undefined25.89 undefined
2029e72.98 undefined0 undefined24.26 undefined
2028e70.74 undefined0 undefined23.31 undefined
2027e70.22 undefined0 undefined22.86 undefined
2026e68.44 undefined0 undefined22.04 undefined
2025e67.3 undefined0 undefined21.49 undefined
202461.78 undefined17.85 undefined7.56 undefined
202352.4 undefined15.17 undefined12.49 undefined
202248.66 undefined18.73 undefined12.11 undefined
202145.34 undefined15.96 undefined10.28 undefined
202043.09 undefined15.49 undefined12.31 undefined
201938.36 undefined15.96 undefined12.88 undefined
201835.71 undefined15.99 undefined12.62 undefined
201731.09 undefined14.07 undefined2.69 undefined
201630.49 undefined12.98 undefined10.24 undefined
201528.28 undefined11.14 undefined9.06 undefined
201426.06 undefined8.53 undefined6.7 undefined
201324.41 undefined8.06 undefined6.64 undefined
201222.28 undefined7.5 undefined5.61 undefined
201117.09 undefined5.7 undefined4.04 undefined
201015.6 undefined7.22 undefined4.79 undefined
200914.34 undefined6.67 undefined4.51 undefined
200813.96 undefined5.14 undefined3.77 undefined
200713.15 undefined4.67 undefined2.74 undefined
200611.99 undefined4.21 undefined2.48 undefined
20059.88 undefined3.85 undefined2.92 undefined

Amgen business model

Amgen Inc. is a global biotechnology company focused on the development and production of pharmaceuticals. It was founded in 1980 by William K. Bowes Jr. and George B. Rathmann in Thousand Oaks, California/USA. The founders had the vision to create new treatment options for serious diseases such as cancer, autoimmune diseases, and osteoporosis. Amgen faced difficulties in its early days due to limited financial resources and setbacks in research. However, the company succeeded in developing the first recombinant therapeutic protein drug, Erythropoietin (EPO), and bringing it to the market. Today, Amgen has become one of the largest biotechnology companies in the world with over 24,000 employees worldwide. The company is known for its research and development work in oncology, kidney diseases, blood disorders, inflammation, and bone diseases. Amgen's business model involves investing in research and development to develop new drugs and commercialize them in global markets. The company follows a "biological platform" strategy, focusing on biotechnology products based on proteins and antibodies. Amgen has several product lines, including Biologics, Biosimilars, and Small Molecules. Biologics are protein-based drugs manufactured using living cells. Biosimilars are products that have similar structures to existing biologics. Small Molecules are chemically manufactured drugs. Some of Amgen's most well-known products include Epogen and Aranesp (both Erythropoietin-releasing hormones), Neulasta and Neupogen (both granulocyte colony-stimulating factors), Enbrel (a TNF inhibitor for the treatment of rheumatoid arthritis), Prolia and Xgeva (both Denosumab inhibitors for the treatment of osteoporosis), and Blincyto (a bispecific antibody against cancer). Amgen is also involved in cancer immunotherapy and has a range of medications in its portfolio, including a CAR-T immunotherapy used for certain forms of acute lymphoblastic leukemia (ALL). In addition, Amgen specializes in the development of biosimilars. In 2017, the company introduced six biosimilars to the market, including copies of Enbrel and Humira for the treatment of rheumatoid arthritis. Biosimilars have the potential to reduce the costs of patient treatment as they are typically cheaper than the original products. Furthermore, Amgen works closely with other companies and research institutions to develop innovative products and technologies. The company has numerous partnerships and licensing agreements with other companies in the biotech industry to accelerate its growth and expand its product pipeline. Overall, Amgen has successfully established itself as one of the leading biotechnology companies in the world. It is known for its innovative products, investments in research and development, and partnerships with other companies. With its wide product portfolio and commitment to producing high-quality biological products, Amgen will continue to play an important role in the healthcare industry. Amgen is one of the most popular companies on Eulerpool.com.

Amgen SWOT Analysis

Strengths

Amgen Inc. possesses several strengths that contribute to its success in the biotechnology industry. These strengths include:

  • Strong research and development capabilities, allowing the company to innovate and develop cutting-edge biopharmaceutical products
  • Diverse portfolio of products, enabling Amgen to cater to various therapeutic areas and target a wide range of diseases
  • Global presence and established reputation, providing a competitive advantage and facilitating access to international markets
  • Solid financial performance, with consistent revenue growth and strong profitability
  • Robust intellectual property portfolio, safeguarding the company's innovations and providing a barrier to entry for competitors

Weaknesses

Despite its strengths, Amgen Inc. also faces certain weaknesses that may pose challenges to its growth and competitiveness:

  • Dependency on a limited number of blockbuster drugs, making the company vulnerable to patent expiration and generic competition
  • Reliance on external partnerships for some drug development programs, which may introduce uncertainties and potential conflicts of interest
  • Higher production costs compared to traditional pharmaceutical companies due to the complexity of biologics manufacturing processes
  • Occasional regulatory hurdles and legal disputes, leading to delays in product approvals and potential reputational damage

Opportunities

Amgen Inc. can capitalize on various opportunities in the biotechnology market to further enhance its position and drive growth:

  • Increasing demand for biologics and personalized medicine, presenting a significant market potential for Amgen's specialized products
  • Expanding into emerging markets, where there is a growing need for advanced healthcare solutions
  • Investing in research and development to explore new therapeutic areas and expand the company's product pipeline
  • Strategic acquisitions or collaborations to access complementary technologies or gain entry into new markets

Threats

Amgen Inc. must also navigate several threats that could negatively impact its operations and market position:

  • Intense competition from other biotechnology companies and traditional pharmaceutical giants
  • Potential price pressures and reimbursement challenges as payers seek to contain healthcare costs
  • Increasingly stringent regulatory requirements and evolving regulations that may impact product development and commercialization
  • Rapid technological advancements and potential disruption from biosimilars or other competitive innovations

Amgen Revenue by Segment

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Amgen Revenue by Segment

Segmente20232022202120192018
Product sales180 M USD24.8 B USD---
Other revenues1.28 B USD1.52 B USD---

  • 3 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Amgen Revenue by Segment

Segmente20232022202120192018
Product sales--24.3 B USD--
Other products5.26 B USD----
Prolia4.05 B USD----
ENBREL3.7 B USD----
Nplate1.48 B USD848 M USD---
Otezla2.19 B USD----
XGEVA2.11 B USD----
Other revenues--1.68 B USD--
Repatha1.64 B USD----
KYPROLIS1.4 B USD----
Aranesp1.36 B USD----
EVENITY1.16 B USD----
Vectibix984 M USD----
BLINCYTO861 M USD----
TEPEZZA448 M USD----
KRYSTEXXA272 M USD----

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Amgen Revenue by Segment

Segmente20232022202120192018
Other---1.16 B USD295 M USD

Amgen Revenue by Region

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Amgen Revenue by Segment

DateRest of the world (ROW)ROWU.SUnited States
2023-8.38 B USD19.81 B USD-
2018-5.39 B USD-18.36 B USD
2017-4.82 B USD-18.03 B USD
20164.67 B USD--18.33 B USD
2015-4.5 B USD-17.17 B USD
20144.67 B USD--15.4 B USD
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Amgen Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Amgen historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Amgen shares outstanding

The number of shares was Amgen in 2024 — This indicates how many shares 541 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Amgen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Amgen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Amgen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Amgen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Amgen stock splits

In Amgen's history, there have been no stock splits.

Amgen dividend history and estimates

In 2024, Amgen paid a dividend amounting to 9.13 undefined. Dividend means that Amgen distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Amgen provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Amgen’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Amgen's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Amgen Dividend History

DateAmgen Dividend
2030e16.46 undefined
2029e15.4 undefined
2028e14.79 undefined
2027e14.58 undefined
2026e13.93 undefined
2025e4.76 undefined
2011e0.31 undefined
2025e4.76 undefined
20249.13 undefined
20238.64 undefined
20227.95 undefined
20217.22 undefined
20206.56 undefined
20195.95 undefined
20185.41 undefined
20174.77 undefined
20164.15 undefined
20153.37 undefined
20142.62 undefined
20132.02 undefined
20121.55 undefined
2011e0.92 undefined

Amgen dividend payout ratio

In 2024, Amgen had a payout ratio of 64.69%. The payout ratio indicates the percentage of the company's profits that Amgen distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Amgen represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Amgen could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Amgen's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Amgen Payout Ratio History

DateAmgen Payout ratio
2030e63.58 %
2029e63.49 %
2028e63.47 %
2027e63.78 %
2026e63.21 %
2025e63.43 %
202464.69 %
202361.52 %
202264.08 %
202168.48 %
202051.99 %
201945.03 %
201841.84 %
2017256.51 %
201639.06 %
201534.88 %
201445.52 %
201328.31 %
201225.67 %
201113.86 %
201061.52 %
200961.52 %
200861.52 %
200761.52 %
200661.52 %
200561.52 %
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Amgen.

Amgen latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20255.39 6.02  (11.64 %)2025 Q2
3/31/20254.39 4.9  (11.73 %)2025 Q1
12/31/20245.18 5.31  (2.49 %)2024 Q4
9/30/20245.22 5.58  (6.97 %)2024 Q3
6/30/20245.11 4.97  (-2.66 %)2024 Q2
3/31/20243.95 3.96  (0.31 %)2024 Q1
12/31/20234.7 4.71  (0.27 %)2023 Q4
9/30/20234.77 4.96  (4.08 %)2023 Q3
6/30/20234.58 5  (9.11 %)2023 Q2
3/31/20233.93 3.98  (1.19 %)2023 Q1
1
2
3
4
5
...
12

Eulerpool ESG Scorecard© for the Amgen stock

Eulerpool World ESG Rating (EESG©)

85/ 100

🌱 Environment

89

👫 Social

99

🏛️ Governance

67

Environment

Scope 1 - Direct Emissions
147,000
Scope 2 - Indirect emissions from purchased energy
128,000
Scope 3 - Indirect emissions within the value chain
1,705,000
Total CO₂ emissions
275,000
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees53
Percentage of women in management
Percentage of Asian employees20
Share of Asian management
Percentage of Hispanic/Latino employees23
Hispano/Latino Management share
Percentage of Black employees5
Black Management Share
Percentage of white employees48
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Amgen shareholders

%
Name
Stocks
Change
Date
9.88299 % The Vanguard Group, Inc.53,466,984832,2406/30/2025
5.42644 % State Street Global Advisors (US)29,357,026177,0356/30/2025
5.32904 % BlackRock Institutional Trust Company, N.A.28,830,115326,4276/30/2025
3.49552 % Capital International Investors18,910,7763,775,9116/30/2025
3.11638 % Capital World Investors16,859,598157,9896/30/2025
2.40640 % Geode Capital Management, L.L.C.13,018,617291,2716/30/2025
2.38330 % Charles Schwab Investment Management, Inc.12,893,677687,7356/30/2025
2.04156 % Invesco Capital Management (QQQ Trust)11,044,822-64,3777/31/2025
1.96520 % PRIMECAP Management Company10,631,709-1,756,5866/30/2025
1.62986 % Morgan Stanley Smith Barney LLC8,817,53791,9466/30/2025
1
2
3
4
5
...
10

Amgen Executives and Management Board

Mr. Robert Bradway

(61)
Amgen Chairman of the Board, President, Chief Executive Officer (since 2007)
Compensation 22.64 M

Mr. Murdo Gordon

(57)
Amgen Executive Vice President - Global Commercial Operations
Compensation 8.24 M

Dr. David Reese

(61)
Amgen Executive Vice President, Chief Technology Officer
Compensation 7.9 M

Mr. Peter Griffith

(65)
Amgen Chief Financial Officer, Executive Vice President
Compensation 7.57 M

Mr. Jonathan Graham

(63)
Amgen Executive Vice President, General Counsel, Secretary
Compensation 7.24 M
1
2
3
4
...
5

Amgen Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
American Renal Associates Holdings Inc Stock
American Renal Associates Holdings Inc
SupplierCustomer0,960,82-0,200,57
Roche Holding AG Stock
Roche Holding AG
SupplierCustomer0,96-0,740,22-0,18-0,18
Ono Pharmaceutical Co., Ltd. Stock
Ono Pharmaceutical Co., Ltd.
SupplierCustomer0,860,74
Bayer Aktiengesellschaft Stock
Bayer Aktiengesellschaft
SupplierCustomer0,840,110,850,790,75
Insulet Corporation Stock
Insulet Corporation
SupplierCustomer0,84-0,650,13-0,18-0,49-0,44
Novartis AG Stock
Novartis AG
SupplierCustomer0,81-0,59-0,46-0,08-0,07
BlackLine Stock
BlackLine
SupplierCustomer0,800,07-0,05-0,67-0,56-0,32
NEC Stock
NEC
SupplierCustomer0,790,39-0,03-0,35-0,70-0,14
Bright Horizons Family Stock
Bright Horizons Family
SupplierCustomer0,77-0,66-0,05-0,14-0,22-0,09
Sartorius Stedim Biotech Stock
Sartorius Stedim Biotech
SupplierCustomer0,76-0,110,28-0,56-0,54-0,54
1
2
3
4
5
...
7

Most common questions regarding Amgen

What values and corporate philosophy does Amgen represent?

Amgen Inc represents values such as integrity, excellence, and a commitment to patients. The corporate philosophy of Amgen focuses on innovative science, delivering life-changing medicines, and addressing unmet medical needs. Amgen aims to improve the health and well-being of individuals worldwide through their cutting-edge research and development efforts. With a strong emphasis on scientific rigor, ethical practices, and patient-centered approach, Amgen is dedicated to pioneering breakthrough therapies to advance medical care and make a positive impact on society.

In which countries and regions is Amgen primarily present?

Amgen Inc is primarily present in the United States, with its headquarters located in Thousand Oaks, California. The company also has a significant presence in various other countries and regions including Europe, Canada, Japan, and Australia. With a global reach, Amgen Inc operates in many key markets worldwide, leveraging its expertise and innovative portfolio of biopharmaceutical products to improve patients' lives.

What significant milestones has the company Amgen achieved?

Amgen Inc has achieved several significant milestones throughout its history. It pioneered the development and commercialization of biotechnology-based medicines, leading to groundbreaking treatments for various diseases. Notably, Amgen's introduction of Epogen revolutionized the treatment of anemia in patients with chronic kidney disease. The company also played a crucial role in advancing the science of targeted therapies with the launch of drugs like Neulasta and Neupogen, enhancing cancer patient care. Additionally, Amgen has expanded its portfolio with innovative drugs addressing osteoporosis, psoriasis, and migraine prevention. Through continuous research and advancements, Amgen Inc remains at the forefront of biopharmaceutical innovation.

What is the history and background of the company Amgen?

Amgen Inc. is a biotechnology company that was founded in 1980. It has its headquarters in Thousand Oaks, California. The company specializes in developing and manufacturing human therapeutics. Amgen Inc. has a rich history of groundbreaking innovations and advancements in the field of biotechnology. It has introduced numerous successful drugs and therapies, including Epogen, Neupogen, and Enbrel, which have had a significant impact on the treatment of various diseases. Amgen Inc. has grown into one of the largest biotechnology companies globally and continues to strive for advancements in medical science to improve patients' lives.

Who are the main competitors of Amgen in the market?

The main competitors of Amgen Inc in the market are Johnson & Johnson, Novartis AG, Pfizer Inc, and Roche Holding AG.

In which industries is Amgen primarily active?

Amgen Inc is primarily active in the biotechnology industry.

What is the business model of Amgen?

Amgen Inc is a leading biotechnology company with a strong business model focused on discovering, developing, and delivering innovative human therapeutics. The company operates through two main segments: Amgen's innovative medicines segment and its biosimilars segment. Amgen's innovative medicines segment focuses on the development and commercialization of innovative products in the areas of oncology, cardiovascular disease, inflammation, bone health, and neuroscience. The biosimilars segment aims to offer more affordable alternatives to existing biological therapies. With a commitment to research and development, Amgen Inc continually strives to address unmet medical needs and improve patients' lives.

What is the P/E ratio of Amgen 2025?

The P/E ratio cannot be calculated for Amgen at the moment.

What is the P/S ratio of Amgen 2025?

The P/S cannot be calculated for Amgen currently.

What is the Quality Investing of Amgen?

The Quality Investing for Amgen is 6/10.

What is the revenue of Amgen 2025?

The expected Amgen revenue is 36.41 B USD.

How high is the profit of Amgen 2025?

The expected Amgen profit is 11.63 B USD.

What is the business model of Amgen

Amgen Inc. is a biotechnology company that focuses on the development, manufacturing, and marketing of biopharmaceuticals. The company was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen is a key player in the biotechnology field with over 21,000 employees worldwide. Amgen has several divisions, including oncology, hematology, nephrology, bone metabolism, and inflammation. In oncology, Amgen offers various drugs for the treatment of cancer, including Blincyto, Vectibix, and Neulasta. In hematology, the company has developed Aranesp and Epogen for the treatment of anemia. Additionally, Amgen also offers various products for the treatment of kidney diseases such as Sensipar and Parsabiv. In the field of bone metabolism, Amgen provides medications for the treatment of osteoporosis, such as Prolia and Xgeva. In the field of inflammation, Amgen has developed Enbrel for the treatment of rheumatoid arthritis and other inflammatory diseases. Amgen also holds a significant position in the biosimilars market. Biosimilars are imitations of biological drugs that are already on the market. They allow patients to access more affordable treatment options while still providing the same effectiveness and safety as the original product. Amgen has several biosimilars on the market, including Amgevita and Mvasi. Amgen's business model is based on the development of new biopharmaceuticals and biosimilars. The company invests significant financial resources in research and development to create innovative products that aim to improve the health and well-being of patients. Amgen also collaborates closely with other companies and research institutions to find creative solutions for medical challenges. To implement its business model, Amgen has built a global network of production and distribution centers to distribute its products worldwide. The company also has a team of disease-fighting experts, as well as researchers and engineers who work closely together to develop and improve new products. Overall, Amgen has a strong business model based on the development of biopharmaceuticals and biosimilars. The company produces high-quality products to enhance the health of patients worldwide. With a dedicated team of professionals focusing on research, development, and disease-fighting, Amgen is well-positioned to continue creating innovative solutions for medical challenges and expanding its market share.

What is the Amgen dividend?

Amgen pays a dividend of 7.76 USD distributed over 4 payouts per year.

How often does Amgen pay dividends?

Amgen pays out a dividend 4 times a year.

What is the Amgen ISIN?

The ISIN of Amgen is US0311621009.

What is the Amgen WKN?

The WKN of Amgen is 867900.

What is the Amgen ticker?

The ticker of Amgen is AMGN.

How much dividend does Amgen pay?

Over the past 12 months, Amgen paid a dividend of 9.13 USD . This corresponds to a dividend yield of about . For the coming 12 months, Amgen is expected to pay a dividend of 13.93 USD.

What is the dividend yield of Amgen?

The current dividend yield of Amgen is .

When does Amgen pay dividends?

Amgen pays a quarterly dividend. This is distributed in the months of December, March, June, September.

How secure is the dividend of Amgen?

Amgen paid dividends every year for the past 20 years.

What is the dividend of Amgen?

For the upcoming 12 months, dividends amounting to 13.93 USD are expected. This corresponds to a dividend yield of 4.71 %.

In which sector is Amgen located?

Amgen is assigned to the 'Health' sector.

Wann musste ich die Aktien von Amgen kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Amgen from 9/12/2025 amounting to 2.38 USD, you needed to have the stock in your portfolio before the ex-date on 8/22/2025.

When did Amgen pay the last dividend?

The last dividend was paid out on 9/12/2025.

What was the dividend of Amgen in the year 2024?

In the year 2024, Amgen distributed 8.64 USD as dividends.

In which currency does Amgen pay out the dividend?

The dividends of Amgen are distributed in USD.

All fundamentals about Amgen

Our stock analysis for Amgen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amgen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.